Welcome to Traders.com Advantage!

TECHNICAL INDICATORS  |  February 3, 2017
Gilead Sciences and the Ulcer Index
One of the worst performing sectors this past year has been the Health Care sector, and of its sub-sectors, Biotechnology was one of the poorest performers. Gilead Sciences (GILD), a component of that sub-sector lost about 21% over the past year, making it one of the weakest performers year-to-date in its group. A quick glance at its chart shows it still in a steady down trend. But we all know that nothing lasts forever and S&P 500 companies likely will not fall to zero. So, are there any early shoots of positivity which suggest we might be wise to start giving GILD a closer look for a long play?
by Stella Osoba, CMT

You must be a registered member of STOCKS & COMMODITIES magazine to read the article you’ve requested.

Simply fill in your name and address and submit this form to us to receive your FREE TRIAL subscription to STOCKS & COMMODITIES.

This will begin your trial subscription at the special introductory rate of only $89.99 for 1 year. You will receive a trial issue of the magazine in the mail and also be able to access a sample digital issue of the magazine online in our subscriber area. In addition, you will have access to our online publications Working Money and Traders.com Advantage for 30 days!. Your log-in information will also be provided via the Email address you submit with the form below.

If you are not satisfied with your sample issue of Stocks & Commodities magazine, just return your bill marked “cancel” and owe nothing. The sample issue is yours to keep!

HELPQuestions or Comments? Send message to: Circ@Traders.com